These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38020293)

  • 1. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis.
    Li Z; Xu Y; Qu W; Liu P; Zhu Y; Li H; Guo Y; Liu X
    Oncol Lett; 2023 Dec; 26(6):534. PubMed ID: 38020293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study.
    Sun L; Hu Z; Xie W; Yang Z; Zeng H; Zhang Y; Chen M; Hu D; Zhou Z; Pan Y
    BMC Cancer; 2024 Sep; 24(1):1168. PubMed ID: 39300392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Jiang P; Chen C; Tian J; Yang F; Jiang ZY; Hu AX; Liu B
    Acad Radiol; 2024 Oct; ():. PubMed ID: 39384510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.
    Wang W; Li R; Li H; Wang M; Wang J; Wang X; Zhou Q
    Immunotargets Ther; 2024; 13():399-412. PubMed ID: 39184311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J; Yang B; Teng Z; Liu Y; Li D; Qu X
    Front Immunol; 2024; 15():1430196. PubMed ID: 39355238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Liu Q; Zhang Y; Zhang J; Chen L; Yang Y; Liu Y
    Front Oncol; 2024; 14():1374149. PubMed ID: 39077472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of HAIC combined with tyrosine kinase inhibitors
    Yang M; Jiang X; Liu H; Zhang Q; Li J; Shao L; Zhao L
    Front Pharmacol; 2024; 15():1410767. PubMed ID: 39144625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan.
    Wu JS; Hong TC; Wu HT; Lin YJ; Chang TT; Wang CT; Liu WC; Hsieh MT; Wu IC; Chen PJ; Chen CY; Lin SH; Chuang CH; Han MZ; Chen HP; Tsai HM; Kuo HY
    J Gastrointest Oncol; 2023 Apr; 14(2):849-862. PubMed ID: 37201085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
    Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
    Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
    J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.
    Tan HY; Liu SQ; Zheng JL; Liu HY; Liu YH; Dai GH; Feng HG
    Abdom Radiol (NY); 2024 Oct; ():. PubMed ID: 39392475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R; Wang X; Li H; Wang M; Wang J; Wang W; Zhou Q
    J Hepatocell Carcinoma; 2024; 11():1727-1740. PubMed ID: 39281003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
    J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
    Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.